Repare Therapeutics Shares Rise 18% After News of Roche Deal
marketwatch.com
news
2022-06-01 22:03:00

By Stephen Nakrosis Shares of Repare Therapeutics Inc. were trading higher in Wednesday's after-hours session, following news the company entered a worldwide license and collaboration agreement with Roche to develop and commercialize camonsertib. Camonsertib, or RP-3500, is being developed to treat tumors with specific synthetic-lethal genomic alterations, the company said. Under the terms of the deal, "Roche will assume development of camonsertib with the potential to expand development into additional tumors and multiple combination studies," Repare said.
